UFP Technologies Director Cynthia Feldmann Sells 1,000 Shares

Cynthia L. Feldmann, a Director at UFP Technologies (NASDAQ:UFPT), sold 1,000 shares of common stock on Aug. 13, 2026, according to a SEC Form 4 filing.

Transaction summary

Transaction value based on SEC Form 4 weighted average sale price ($324.26); post-transaction value based on Aug. 13, 2026, market close ($319.86).

Key questions

• What are the primary operational metrics for UFP Technologies?
  UFP Technologies specializes in the engineering and custom fabrication of components, subassemblies, and packaging for the medical sector. The Newburyport-based company employs 4,846 full-time employees and has a market capitalization of $2.3 billion.
  • Sector: Healthcare
  • Industry: Medical Devices
  • Trailing twelve-month revenue: $631.6 million
  • Trailing twelve-month net income: $72.3 million
• How does this disposition affect the insider's total equity position?
  The sale of 1,000 shares reduced Feldmann's direct stake to 4,476 shares, which represents approximately 82% of her pre-transaction holdings. This remaining direct position is valued at $1.4 million based on the market close on the day of the transaction.
• What is the recent market context for this transaction?
  Shares were priced at $321.76 as of the Aug. 14, 2026, market close, following a year of growth where the stock delivered a 41% return as of the transaction date. The execution price of $324.26 per share was slightly higher than the $319.86 close on the day of the trade.
• What is the aggregate insider ownership level in the company?
  Following this transaction, insiders collectively hold a 0.05% stake in the company. The reporting Director's current direct holdings account for a portion of this total insider equity.

Company Overview

Company Snapshot

• UFP Technologies specializes in the engineering and custom fabrication of advanced foam, film, and plastic components, subassemblies, and finished products, with a significant concentration in medical device applications, including single-use devices, disposable wound care, infection control products, and minimally invasive surgical tools.
• The company operates a specialized manufacturing and engineering business model that generates revenue through the design and production of custom-engineered components and finished medical devices for original equipment manufacturers and healthcare providers.
• UFP Technologies serves a diverse customer base across the healthcare and medical device sectors, including medical device manufacturers, hospitals, surgical centers, and other healthcare institutions that require specialized single-patient and single-use medical components.

UFP Technologies is a mid-cap medical device component manufacturer with a market capitalization of $2.3 billion and TTM revenues of $631.6 million, demonstrating strong profitability with TTM net income of $72.3 million. The company has generated significant shareholder value, with a one-year stock price appreciation of 43.5% as of this writing, reflecting investor confidence in its specialized manufacturing capabilities and exposure to growing medical device markets. UFP's competitive advantage derives from its proprietary expertise in advanced foam, film, and plastic engineering combined with its established relationships with leading medical device manufacturers and healthcare providers.

What this transaction means for investors

Feldmann reduced her total holdings from 5,476 shares to 4,476, but this transaction appears to be more about taking some profits off the table while remaining invested in the company's success. The UFP stock price has climbed 45.8% over the last six months alone, while the S&P 500 is up 11.6% in the same period. With the shares surging so much in such a short period of time, that could be what's driving this transaction more than anything else. This trade doesn't appear to represent a signal that shareholders should be worried about the company's future.

The stock doesn't receive much analyst coverage, but of the four analysts who do cover it, they are split. Two of the analysts view UFP as a buy, while the other two view it as a hold. From that group, the median one-year price target for the stock is $355, representing a 19.1% gain from the price as of this writing. The highest price target in the group is $360, representing a 20.8% gain, while the lowest is $350, representing a 17.4% gain.

Jack Delaney has no position in any of the stocks mentioned. The Motley Fool recommends UFP Technologies. The Motley Fool has a disclosure policy.